The aim of the study is to compare the efficacy of Neridronate (NER) and Zoledronate (ZOL) in reducong skeletal morbidity in patients with multiple myeloma.

Intravenous neridronate for treatment of skeletal involvement in patients with multiple myelomaundergoing autologous stem cell transplantation / Pittari, G.; Costi, Daniele; Mangoni, L.; Caramatti, Cecilia; Baroni, Maria Cristina; Rizzoli, V.. - 90(suppl):(2005), pp. S185-S185. (Intervento presentato al convegno 40th Congress of the italian soceity of haematology tenutosi a Bergamo nel JULY 2005).

Intravenous neridronate for treatment of skeletal involvement in patients with multiple myelomaundergoing autologous stem cell transplantation

COSTI, Daniele;CARAMATTI, Cecilia;BARONI, Maria Cristina;
2005-01-01

Abstract

The aim of the study is to compare the efficacy of Neridronate (NER) and Zoledronate (ZOL) in reducong skeletal morbidity in patients with multiple myeloma.
2005
Intravenous neridronate for treatment of skeletal involvement in patients with multiple myelomaundergoing autologous stem cell transplantation / Pittari, G.; Costi, Daniele; Mangoni, L.; Caramatti, Cecilia; Baroni, Maria Cristina; Rizzoli, V.. - 90(suppl):(2005), pp. S185-S185. (Intervento presentato al convegno 40th Congress of the italian soceity of haematology tenutosi a Bergamo nel JULY 2005).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/1440313
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact